{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:44:27Z","timestamp":1792197867289,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Biotechnology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.nbt.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:05:46Z","timestamp":1693793146000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells"],"prefix":"10.1016","volume":"77","author":[{"given":"Kim Anh","family":"Giang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorstein","family":"Boxaspen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Nilvebrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuha","family":"Kosugi-Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje Zandstra","family":"Krokeide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Svensson Gelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Johan","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-6991","authenticated-orcid":false,"given":"Per-\u00c5ke","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.nbt.2023.09.002_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.nbt.2023.09.002_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: designing T-cell engagers with better therapeutic windows","volume":"10","author":"Vafa","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.nbt.2023.09.002_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","article-title":"T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities","volume":"34","author":"Baeuerle","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10.1016\/j.nbt.2023.09.002_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.nbt.2023.09.002_bib6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/eji.202048953","article-title":"Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments","volume":"51","author":"Demaria","year":"2021","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.nbt.2023.09.002_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib8","doi-asserted-by":"crossref","first-page":"2208697","DOI":"10.1080\/19420862.2023.2208697","article-title":"Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors","volume":"15","author":"Whalen","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.nbt.2023.09.002_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1016\/j.nbt.2023.09.002_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","article-title":"Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers","volume":"43","author":"Pinto","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nbt.2023.09.002_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-014-0029-x","article-title":"The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer","volume":"2","author":"Stewart","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nbt.2023.09.002_bib12","doi-asserted-by":"crossref","first-page":"34310","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib13","doi-asserted-by":"crossref","first-page":"15983","DOI":"10.1038\/s41598-018-34258-1","article-title":"A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism","volume":"8","author":"Mahaweni","year":"2018","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.nbt.2023.09.002_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jim.2005.06.018","article-title":"CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells","volume":"304","author":"Bowles","year":"2005","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/j.nbt.2023.09.002_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"issue":"9","key":"10.1016\/j.nbt.2023.09.002_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib17","doi-asserted-by":"crossref","first-page":"1950264","DOI":"10.1080\/19420862.2021.1950264","article-title":"Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors","volume":"13","author":"Wingert","year":"2021","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.nbt.2023.09.002_bib18","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.nbt.2023.09.002_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s44228-022-00023-5","article-title":"Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma","author":"Plesner","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib20","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1073\/pnas.1707856115","article-title":"Affimer proteins inhibit immune complex binding to FcgammaRIIIa with high specificity through competitive and allosteric modes of action","volume":"115","author":"Robinson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/protein\/gzm064","article-title":"Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells","volume":"21","author":"Behar","year":"2008","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.nbt.2023.09.002_bib22","doi-asserted-by":"crossref","first-page":"1005800","DOI":"10.3389\/fimmu.2022.1005800","article-title":"Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.nbt.2023.09.002_bib23","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a novel CD16-specific single-domain antibody into multispecific natural killer cell engagers with potent ADCC","volume":"18","author":"van Faassen","year":"2021","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15384047.2019.1665953","article-title":"Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies","volume":"21","author":"Zhao","year":"2020","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"10.1016\/j.nbt.2023.09.002_bib25","article-title":"Comparative analysis of immune repertoires between bactrian camel's conventional and heavy-chain antibodies","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nbt.2023.09.002_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","article-title":"Practical theoretic guidance for the design of tumor-targeting agents","volume":"503","author":"Wittrup","year":"2012","journal-title":"Methods Enzym"},{"issue":"3","key":"10.1016\/j.nbt.2023.09.002_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blade","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.nbt.2023.09.002_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.nbt.2023.09.002_bib29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"Stahl","year":"2017","journal-title":"Trends Biotechnol"},{"issue":"6","key":"10.1016\/j.nbt.2023.09.002_bib30","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nbt.2023.09.002_bib31","unstructured":"NCI. Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms; 2022. Available from: \u3008https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/multiple-myeloma\u3009."},{"issue":"6","key":"10.1016\/j.nbt.2023.09.002_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/protein\/8.6.601","article-title":"A combinatorial library of an alpha-helical bacterial receptor domain","volume":"8","author":"Nord","year":"1995","journal-title":"Protein Eng"},{"issue":"10","key":"10.1016\/j.nbt.2023.09.002_bib33","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.nbt.2023.09.002_bib34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2125.2006.02771.x","article-title":"Distribution of the FcgammaRIIIa 176 F\/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore","volume":"63","author":"Chong","year":"2007","journal-title":"Br J Clin Pharm"},{"issue":"5","key":"10.1016\/j.nbt.2023.09.002_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK(R)): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"MAbs"},{"issue":"16","key":"10.1016\/j.nbt.2023.09.002_bib36","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.nbt.2023.09.002_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.nbt.2023.09.002_bib38","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/eji.201040335","article-title":"Ligand dimensions are important in controlling NK-cell responses","volume":"40","author":"Brzostek","year":"2010","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib39","doi-asserted-by":"crossref","first-page":"1871171","DOI":"10.1080\/19420862.2020.1871171","article-title":"One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics","volume":"13","author":"Chen","year":"2021","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.nbt.2023.09.002_bib40","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","article-title":"Antibody distance from the cell membrane regulates antibody effector mechanisms","volume":"198","author":"Cleary","year":"2017","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.nbt.2023.09.002_bib41","doi-asserted-by":"crossref","first-page":"1739408","DOI":"10.1080\/19420862.2020.1739408","article-title":"Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors","volume":"12","author":"Hatterer","year":"2020","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.nbt.2023.09.002_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by Anti-FcRH5\/CD3 and is a requirement for Myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.nbt.2023.09.002_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.13464","article-title":"NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion-the differences and similarities","volume":"166","author":"Roe","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.nbt.2023.09.002_bib44","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3389\/fimmu.2020.01635","article-title":"Considerations of antibody geometric constraints on NK cell antibody dependent cellular cytotoxicity","volume":"11","author":"Murin","year":"2020","journal-title":"Front Immunol"},{"issue":"51","key":"10.1016\/j.nbt.2023.09.002_bib45","doi-asserted-by":"crossref","first-page":"19899","DOI":"10.1074\/jbc.RA118.005273","article-title":"A single amino acid distorts the Fc gamma receptor IIIb\/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a","volume":"293","author":"Roberts","year":"2018","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.nbt.2023.09.002_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.exphem.2008.11.006","article-title":"Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils","volume":"37","author":"Shibata-Koyama","year":"2009","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.nbt.2023.09.002_bib47","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule","volume":"55","author":"Sorensen","year":"2014","journal-title":"J Nucl Med"}],"container-title":["New Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678423000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678423000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:08:46Z","timestamp":1761732526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871678423000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":47,"alternative-id":["S1871678423000456"],"URL":"https:\/\/doi.org\/10.1016\/j.nbt.2023.09.002","relation":{},"ISSN":["1871-6784"],"issn-type":[{"value":"1871-6784","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"New Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbt.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}